GlassScriptPhysician profile
Igor G Turok
NPI 1972575801
$2,723.84
in general payments reported to CMS, 2019-2025
27 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Pain Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $405).
See the full distribution for Pain Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $167 · 2021: $514 · 2022: $277 · 2023: $309 · 2024: $178 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.07 | 2021-2024 | Ubrelvy, Qulipta |
| Collegium Pharmaceutical, INC. | $404.38 | 2019-2025 | Belbuca |
| Scilex Pharmaceuticals INC. | $197.47 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $155.50 | 2019-2023 | Dysport |
| Arbor Pharmaceuticals, INC. | $148.95 | 2019-2021 | |
| Merz North America, INC. | $145.84 | 2019-2025 | |
| Pfizer INC. | $113.95 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $102.32 | 2021 | |
| Saluda Medical Americas, INC. | $64.30 | 2024 | Evoke |
| Novartis Pharmaceuticals Corporation | $60.25 | 2019 | |
| Daiichi Sankyo INC. | $54.47 | 2019 | |
| Allergan, INC. | $52.76 | 2020 | |
| Depuy Synthes Sales INC. | $46.69 | 2019 | |
| Horizon Therapeutics Plc | $46.00 | 2019-2021 | |
| Lilly USA, LLC | $34.30 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $31.65 | 2019 | |
| Biodelivery Sciences International, INC. | $30.23 | 2019 | |
| Galderma Laboratories, L.P. | $27.40 | 2024-2025 | Dysport |
| Takeda Pharmaceuticals U.S.A., INC. | $24.16 | 2019 | |
| Dermira, INC. | $22.18 | 2019 | |
| Vertical Pharmaceuticals, LLC | $21.87 | 2019 | |
| Grifols USA, LLC | $21.02 | 2019 | |
| Genzyme Corporation | $18.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.30 | 2019 | |
| Shionogi INC | $16.24 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.90 | 2019 | |
| Kaleo, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Turok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.